Manual práctico de Trombosis y Hemostasia de la SETH

— 1 3 8 — I I . PA T O LO G Í A D E L A H E M O ST A S I A BIBLIOGRAFÍA 1. Vainchenker W, Kralovics R. Genetic basis and molecular pa- thophysiology of classical myeloproliferative neoplasms. Blood 2017;129(6):667-79. 2. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al.Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23(10):2224-32. 3. Marchioli R, Finazzi G, Specchia G, Masciulli A , Mennitto MR, Ci- lloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368(1):22-33. 4. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rode- ghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011;117(22):5857-9. 5. Falanga A, Marchetti M. Thrombosis in myeloproliferative neo- plasms. SemThromb Hemost 2014;40(3):348-58. 6. Kaifie A, Kirschner M,Wolf D, Maintz M, Hänel N, Gattermann E, et al. Bleeding, thrombosis, and anticoagulation in myeloprolifera- tive neoplasms (MPN): analysis from the German SAL-MPN-re- gistry. J Hematol Oncol 2016;9:18. 7. Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 2014;124(24):3529-37. 8. De Grandis M, Cambot M,Wautier MP, Cassinat B, Chomienne C, Colin Y, et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood 2013;121(4):658-65. 9. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122(13):2176-84. 10. Arellano-Rodrigo E, Álvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational sta- tus. Haematologica 2006;91(2):169-75. 11. Panova-Noeva M, Marchetti M, Spronk HM, Russo L, Diani E, Fi- nazzi G, et al. Platelet-induced thrombin generation by the cali- brated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 2011;86(4):337-42. 12. Abbonante V, Chitalia V, Rosti V, Leiva O, Matsuura S, Balduini A, et al. Upregulation of lysyl oxidase and adhesion to collagen of human megakaryocytes and platelets in primary myelofibrosis. Blood 2017;130(6):829-31. 13. Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Fi- nazzi G, et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essen- tial thrombocythemia and polycythemia vera patients. Blood 2011;118(9):2599-601. 14. Torregrosa JM, Ferrer-Marín F, Lozano ML, Moreno MJ, Martínez C, Antón AI, et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br J Haematol 2016;172(5):813-5. 15. Rumi E, Cazzola M. Diagnosis, risk stratification, and respon- se evaluation in classical myeloproliferative neoplasms. Blood 2017;129(6):680-92. 16. Marchetti M,Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Ram- baldi A, et al. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 2014;89(1):68-73. 17. Charpentier A, Lebreton A, Rauch A, Bauters A,Trillot N, Nibou- rel O, et al. Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombo- cythemia. Haematologica 2016;101(9):e365-8. 18. Dienava-Verdoold I,Marchetti MR,te Boome LC,Russo L,FalangaA, Koene HR, et al. Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haemato- logical malignancies.Thromb Haemost 2012;107(3):468-76. 19. Malecki R, Gacka M, Kuliszkiewicz-Janus M, Jakobsche-Policht U, Kwiatkowski J, Adamiec R, et al. Altered plasma fibrin clot pro- perties in essential thrombocythemia. Platelets 2016;27(2):110-6. 20. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH, et al. The paradox of platelet activation and impaired function: platelet-vonWillebrand factor interactions, and the etio- logy of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Sem Thromb Hemost 2006;32(6):589-604. 21. Moore SF, Hunter RW, Harper MT, Savage JS, Siddiq S,Westbury S, et al. Dysfunction of the PI3 kinase/Rap1/integrin alpha(IIb) beta(3) pathway underlies ex vivo platelet hypoactivity in essen- tial thrombocythemia. Blood 2013;121(7):1209-19. 22. Lancellotti S, Dragani A, Ranalli P, Petrucci G, Basso M, Tartaglio- ne R, et al. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost 2015;13(7): 1226-37. 23. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griessha- mmer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761-70. 24. Barbui T, Finazzi G, Carobbio A, Abou Hussein AK, Elala YC, Hanson C, et al. Development and validation of an Internatio- nal Prognostic Score of thrombosis in World Health Organiza- tion-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120(26):5128-33. 25. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009;114(4):759-63. 26. Tefferi A, Barbui T. Polycythemia vera and essential thrombo- cythemia: 2017 update on diagnosis, risk-stratification, and mana- gement. Am J Hematol 2017;92(1):94-108.